AzTrials
AzTrials

Lymphedema of FaceMLD-HNNCT07215169

Manual Lymph Drainage for External Lymphedema

A study testing HIT and LIT in people with Lymphedema of Face and Neoplasms, run by Lund University at 1 site in Sweden.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study will evaluate the feasibility of a randomized controlled trial. The future randomized controlled trial will compare two groups following different intensities of manual lymphatic drainage for external head- and neck lymphedema among persons treated with radiotherapy for head- and neck cancer. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
HIT and LIT
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteSweden
Study dates
1 Oct 2025to Jun 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • • a previous diagnosis of oropharyngeal cancer (all histological types are accepted)
  • curative treatment with (chemo)radiotherapy to at least 68Gy at the primary site completed no more than 1 year before the study inclusion
  • age >18 years
  • ability to give written and informed consent.

Who cannot join

  • • pregnancy
  • surgery or Botox injections in the tissue of the head and neck area
  • Locoregional deep infection i.e., suspected abscess at the scheduled time points for measurements.
  • prior daily treatment with Self MLD
  • other treatment of head and neck lymphedema, for example compression
  • psychiatric disorders
  • substance abuse problems

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Eva Ekvall Hansson, Professor, RPT contact

+46462221986

eva.ekvall-hansson@med.lu.se

Agneta Hagren, Registered Nurse contact

+4646175964

agneta.hagren@med.lu.se

Sweden1 site, 1 recruiting
  • Lund university

    Lund, Skåne County, 22100

    Eva Ekvall Hansson, Professor, 0462221986, eva.ekvall_hansson@med.lu.se

    Eva Ageberg, Professor

    Recruiting

Other trials in Sweden

About this study

Official title: The Effect of Manual Lymph Drainage for Cancer Treatment-related External Lymphedema in the Head and Neck - a Pilot and Feasibility Study of a Randomized Controlled Trial

This study will evaluate the feasibility of a randomized controlled trial. The future randomized controlled trial will compare two groups following different intensities of manual lymphatic drainage for external head- and neck lymphedema among persons treated with radiotherapy for head- and neck cancer.

Read the detailed description

Methods Study setting The study will be conducted at the Department of Otorhinolaryngology, Head \& Neck Surgery, Skåne University Hospital, Lund, Sweden, a tertiary referral hospital. All head and neck cancer patients in the Southern Health Care region, with a catchment area of approximately 1.2 million inhabitants, are treated at Skåne University Hospital. The patients will be assessed by the study coordinator to be able to follow and complete the intervention.

Recruitmenthttps://register.clinicaltrials.gov/prs/beta/studies/S000EE8A00000009/protocol/conditions?edit=true As part of clinical routine, the patients have a doctor´s visit three months after cancer treatment completion at the Dept. of ORL-HNS Skåne University Hospital, Lund. The assessment of lymphedema will be performed as a part of the clinical examination. Patient who are assessed to have lymphedema (>2 SD of healthy reference values13) and are possible candidates for enrolment will receive oral and written information about the study. If the patient accepts inclusion, a signed consent will be retrieved.

Intervention A: HIT

Highly Intensive Treatment with Self MLD:

Week 1 - 2: 20 strokes at the neck, 20 strokes at the cheek and finally 20 strokes at the neck, at both sides of the neck and face. This treatment should by repeated every two hours during the daytime, approximately 6-8 times a day.

Week 3 - 12: 20 strokes at the neck, 20 strokes at the cheek and finally 20 strokes at the neck, at both sides of the neck and face, once a day.

Intervention B: LIT

Low Intensive Treatment with Self MLD:

Week 1 - 12: 20 strokes at the neck, 20 strokes at the cheek and finally 20 strokes at the neck at both sides of the neck and face, once a day.

Procedure Each participant will receive a study number in order of inclusion. The code key, connecting the personal identity number with the study number, will be kept on aUSB memory stick and securely locked in at the Dept. of ORL-HNS Skåne University Hospital, Lund. Only the researchers mentioned above will have access to the code key.

Data will be retrieved from the medical records and transferred to a digital case report form (CRF)/file. BMI, measurement of tissue water data, and LyQLI questionnaires will be available as physical CRF. Each CRF will be connected to the patient's informed consent and kept securely locked as above. The data on the physical CRF will be transferred to the digital file as above. Data management will be performed according to GDPR 14.

Measurement of tissue water is performed with a lymph scanner (MoistureMeterD) at four measuring point in the head and neck area (table 1). In addition, the neck circumference at three levels will be assessed with a measuring tape (table 2). The assessments will be performed 2 and 12 weeks after interventional therapy. The measurement will be completed by a physiotherapist with specific education of HNL and the handling of the lymph scanner.

Each participant will respond to a lymphedema specific quality-of-life questionnaire, LyQLi, at the same time points as the measurements of tissue water and circumference measurements. The participants will also complete a treatment diary.

Outcomes Feasability outcomes Feasibility of a randomized controlled trial, studying the effect of Self MLD of different intensity over time for persons treated with (chemo)radiotherapy with curative intent for an oropharyngeal cancer.

The change of tissue water and neck circumference in the head and neck area at 2 weeks and 12 weeks after interventional therapy.

Patient related outcomes The difference in QoL, with specific regards to lymphedema, before and after interventional therapy.

Data collection methods

Baseline data are extracted from medical records and include:

  • Diagnosis: subsite and histology type, TNM-classification, stage
  • Age at diagnosis
  • Gender
  • BMI
  • Smoking habits
  • Ratings of physical activity according to Frändin and Grimby

At 14 days and 10 weeks after interventional therapy:

  • BMI/weight
  • Smoking habits
  • Tissue water measurement in the head and neck in a sitting position
  • Ratings of physical activity according to Frändin and Grimby
  • Treatment diary Data analysis 40 patients (20 in each group) will be included in the study. We expect approximately 2/3 of the patients to be male according to the epidemiology of HNC.

Demographic data will be presented with medians and IQR and/or means and standard deviations (continuous variables) or numbers and percent (categorical variables).

ANOVA will be used to evaluate differences between the groups regarding the change in HNL. Wilcoxon signed rank test will be used to evaluate the differences in health related QoL with specific regards to lymphedema before and after the intervention.

Ethics and dissemination Participation in the study is voluntary. All participants can, whenever they want and without leaving any explanation, withdraw their participation. The study does not contain any physical intervention and there is no risk for harm, neither physical nor mental. The study will be performed in accordance with the ethical standards of the responsible committee on human experimentation, the Declaration of Helsinki 15.

Informed consent will be collected by Agneta Hagren and securely stored, see above.

Only the researchers mentioned above will have access to the final trial data set. The results from the study will be published in a peer-reviewed medical journal. Furthermore, the results will be communicated to the participating patients and the head and neck cancer patients' association in Sweden.

Being tested
HIT, LIT
Keywords
Head and neck lymphedema management
Medical subject headings
Neoplasms, Radiation Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HITOther

    Manual Lymph Drainage 20 completions, first over the neck, then the face, and finally the neck again. This is repeated every second hour during the daytime.

  • LITOther

    Manual Lymph Drainage 20 completions, first over the neck, then the face, and finally the neck again once a day.

Study groups in NCT07215169
Study groupRoleWhat they receive
HITExperimentalHigh-intensity treatment with manual lymphedema drainage.
Receives: Other: HIT
LITOtherLow-intensity treatment with manual lymphedema drainage, which is the standard treatment.
Receives: Other: LIT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recruitment rate, retention rate, adverse events, and ability to collect outcomes

    of recruitment rate, calculated as the percentage of individuals who agreed to be in the study among those who were qualified; retention rate, calculated as the percentage of individuals who completed the intervention; the ability to collect data, calculated as the percentage of completed collected data at baseline and follow-up; and adverse events, which is the num-ber of harmful or negative events that may have influenced the study procedure

    Measured: Two and twelve weeks after inclusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Oct 2025
  2. Study start1 Oct 2025
  3. Primary completionDec 2026 (estimated)
  4. Study completionJun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Pilot and feasibility study of a randomized controlled trial
Masking
Double blind
Who is masked
Care provider, Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07215169
Sponsor's protocol ID
2023-04456-01
Other IDs
2023
Acronym
MLD-HN
Status last verified
Oct 2025
First submitted
2 Oct 2025
Last updated
10 Oct 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing HIT and LIT in people with Lymphedema of Face and Neoplasms, run by Lund University at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 10 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Eva Ekvall Hansson, Professor, RPT (+46462221986, eva.ekvall-hansson@med.lu.se), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recruitment rate, retention rate, adverse events, and ability to collect outcomes (time frame: Two and twelve weeks after inclusion). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in